(LOS ANGELES) – August 25, 2023 - An advancement in 3D bioprinting of native-like skeletal muscle tissues has been made by scientists at the Terasaki Institute for Biomedical Innovation (TIBI).
News
News
(LOS ANGELES) – September 22, 2023 - The Terasaki Institute for Biomedical Innovation (TIBI) welcomes Zhaohui Wang, Ph.D., as its new Assistant Professor and Director of Precision Medicine. His main research focus is on discovering innovative bioengineering solutions to combat cancer.
(LOS ANGELES) – August 15, 2023 - A team of researchers from the Terasaki Institute for Biomedical Innovation (TIBI) and the University of Nebraska Medical Center (UNMC) has been awarded a multimillion-dollar grant from the National Institutes of Health to develop a superior, multi-pronged wound treatment for diabetic foot ulcers (DFUs).
(LOS ANGELES) – Scientists from the Terasaki Institute for Biomedical Innovation (TIBI) have developed a nanoengineered bioink with improved bonding and cross-linking capabilities for 3D bioprinting of tumor models. A key component of this bioink is Laponite, highly charged, disk-shaped, crystalline nanoparticles. As explained in their recent paper in Biofabrication, these nanoparticles were shown to enhance the biological signaling that occurs in the tumor microenvironment so that more accurate tumor models can be created for study and anti-tumor drug development.
(LOS ANGELES) – The Terasaki Institute for Biomedical Innovation (TIBI), is pleased to welcome six new members to its Leadership Board. The TIBI Leadership Board is comprised of distinguished individuals who will utilize their expertise to promote key initiatives and to provide valuable guidance on research and innovation strategies.
Scientists Develop Multifunctional Device Which Combines Hemorrhage Treatment and Monitoring Capabilities
(LOS ANGELES) – June 28, 2023 - A multi-faceted device for effectively treating deep, non-compressible, and irregularly-shaped wounds has been engineered by the scientists at the Terasaki Institute for Biomedical Innovation (TIBI). As outlined in their recent paper in Advanced Science, the device provides rapid hemorrhage management, has minimal inflammatory effects, and provides infection control. It also has tunable biodegradation rates, making it usable for both internal and external use, and features sensing capabilities for long-term hemorrhage monitoring. This versatile device is highly beneficial for timely alerts and control of bleeding from surgical wounds, traumatic injuries, and critical illnesses.
Company introduces unique approach to sustainably produced meat
(LOS ANGELES) - The Terasaki Institute for Biomedical Innovation (TIBI) is excited to unveil their first spinout company, Omeat, an organization dedicated to technology for the sustainable production of beef and other meats on a global scale. Omeat produces cultivated meat, using cost-effective, humane, and efficient methods to collect regenerative factors for cell cultivation from healthy, living cows.
(WOODLAND HILLS, CA) – The Terasaki Institute for Biomedical Innovation (TIBI), a non-profit research organization devoted to developing bioengineered systems, devices, and technology for biomedical applications, held a Grand Opening celebration at their newest research facility in Woodland Hills. The event drew almost 100 guests, which included local dignitaries, members of the Terasaki family, TIBI faculty and staff, and members of the building’s design and construction teams.